What Is Dysplasia of the Esophagus and How Is It Treated?

Dysplasia of the esophagus refers to abnormal, precancerous cell changes in the lining of the esophagus, most commonly arising in tissue already affected by Barrett’s esophagus. It sits on a spectrum between harmless cell changes and esophageal adenocarcinoma, and how aggressively it needs to be treated depends on its grade and extent. Treatment ranges from watchful waiting with acid-suppressing medication to endoscopic ablation procedures that can eliminate the abnormal tissue without surgery.

How Esophageal Dysplasia Develops

The overwhelming majority of esophageal dysplasia cases grow out of Barrett’s esophagus, a condition in which the normal flat (squamous) lining of the lower esophagus is gradually replaced by a columnar lining that looks more like intestinal tissue. This replacement happens in response to chronic acid and bile exposure from gastroesophageal reflux disease (GERD). The body essentially swaps in tougher cells as a wound-healing response, but those replacement cells carry their own risks.

Acid and bile salts from reflux directly damage DNA in esophageal cells. Laboratory studies show that acidified conditions cause DNA strand breaks in a dose- and time-dependent way, and that specific bile compounds like sodium deoxycholate add further damage even at neutral pH.¹ Over years, this accumulating genetic damage can push the metaplastic Barrett’s tissue through increasingly disordered growth patterns, eventually crossing the line into what pathologists call dysplasia. That crossing point is where cancer risk begins to climb meaningfully.

Low-Grade Versus High-Grade Dysplasia

Dysplasia is graded into two tiers, and the distinction matters enormously for what happens next.

Low-grade dysplasia (LGD) means the cells look abnormal under the microscope but the architectural distortion is mild. Many people with LGD never progress further, but a subset do. In one cohort of U.S. veterans, roughly one in four patients with confirmed LGD went on to develop either high-grade dysplasia or adenocarcinoma over a median follow-up of about four years. Persistent LGD that showed up on repeat biopsies carried about four times the risk of progression compared to LGD that wasn’t confirmed on a second look.²

High-grade dysplasia (HGD) is more worrying. The cells are severely disordered, and the tissue may already harbor cancer that hasn’t been caught by biopsy. Reviews of patients who underwent esophageal removal for HGD found that the reported rate of unsuspected cancer in the resected tissue ranged widely, from virtually zero to as high as three-quarters of cases depending on the study and biopsy protocol used beforehand.³ Whether HGD is focal (limited to a small area) or diffuse also changes the picture. Patients with diffuse HGD had a roughly three-and-a-half-fold higher risk of progressing to cancer compared to those with focal HGD, and three-year cancer-free survival was only about 44% for diffuse HGD versus 86% for focal disease.⁴

How Dysplasia Is Found and Diagnosed

Finding dysplasia requires upper endoscopy with biopsies, and the biopsy strategy matters more than most patients realize. The standard approach, called the Seattle protocol, involves taking tissue samples every one to two centimeters throughout the Barrett’s segment in all four quadrants of the esophagus, plus targeted biopsies of anything that looks visually abnormal. This systematic, somewhat tedious protocol consistently outperforms relying solely on what the endoscopist can see, even with modern high-definition equipment.

In one tertiary-center database, about 73% of dysplasia cases were picked up by the random four-quadrant biopsies rather than targeted ones, and the advantage was especially stark for low-grade dysplasia, where over 90% of cases came from the random sampling.⁵ A larger study found similar numbers, with the Seattle protocol responsible for about 80% of dysplasia diagnoses, particularly for LGD cases that technology-assisted targeted biopsies missed.⁶ The take-home message: if your endoscopist skips the systematic four-quadrant biopsies and relies only on what looks suspicious, dysplasia can be missed.

Newer imaging tools are being explored as supplements. Confocal laser endomicroscopy provides images at roughly a thousand-fold magnification, essentially giving a live “optical biopsy” during the procedure.⁷ Its sensitivity for detecting dysplasia sits around 76% and its specificity around 79%, promising but not yet reliable enough to replace conventional biopsies.⁸

Why Pathologists Sometimes Disagree on the Grade

One of the more frustrating realities of esophageal dysplasia is that pathologists often disagree about what they’re seeing, particularly when it comes to low-grade dysplasia. A multi-center study involving pathologists in both the United States and Europe found that inter-observer agreement for LGD was extremely poor. When all cases were considered, the statistical agreement for LGD was barely above chance. Agreement improved substantially when pathologists made their diagnoses with high confidence, but for routine, less clear-cut cases, the variability was striking.⁹

Agreement gets better when pathologists can review a patient’s entire set of biopsies rather than individual slides in isolation. Under those conditions, the agreement for “any dysplasia versus none” reaches what’s considered substantial.¹⁰ This is why guidelines recommend that a diagnosis of dysplasia, especially LGD, be confirmed by a second expert pathologist before any major treatment decisions are made. If you’ve been told you have low-grade dysplasia, getting that second pathology opinion is standard practice, not an unusual request.

Risk Factors That Push Dysplasia Toward Cancer

Not everyone with Barrett’s esophagus or even low-grade dysplasia will progress. Several factors tilt the odds. Longer duration of reflux symptoms is independently associated with higher risk, and having low-grade dysplasia already present is itself one of the strongest predictors of moving to HGD or cancer.¹¹ Older age, abdominal obesity, and caffeine intake have also been linked to increased risk. Interestingly, statin use and SSRI use each appeared to lower the risk of progressing to HGD or cancer by roughly half or more in one large analysis, though the reasons are not entirely clear.¹²

At the molecular level, mutations in the TP53 gene appear to be among the most telling warning signs. In one study, TP53 mutations were found in nearly half of Barrett’s tissue samples from patients who later progressed to HGD or cancer, compared to only 5% of non-progressors. Having a TP53 mutation increased the adjusted risk of progression almost fourteen-fold.¹³ This kind of molecular testing is not yet routine but could eventually help doctors identify which patients with Barrett’s need aggressive intervention and which can safely be monitored.

Endoscopic Treatment Options

The landscape of treatment has shifted dramatically over the past two decades. For most patients with confirmed dysplasia, endoscopic therapy has become the first-line approach, avoiding the major risks of open surgery while achieving comparable outcomes.

Radiofrequency ablation (RFA) is the most studied endoscopic technique. A landmark randomized trial found that RFA eliminated dysplasia in about 90% of patients with LGD and 81% of patients with HGD, compared to roughly 20% in the sham-treated control groups. RFA also significantly reduced disease progression and the development of cancer. The procedure was not without side effects: esophageal stricture (narrowing) occurred in about 6% of treated patients, and some had chest pain or, rarely, bleeding.¹⁴

When there is a visible raised or irregular lesion within the Barrett’s segment, endoscopic resection comes before ablation. The two main resection techniques are endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). EMR uses a cap-based approach and works well for smaller, superficial lesions under about 15 to 20 millimeters. Larger lesions require piecemeal removal, which can leave residual tissue and makes it harder for pathologists to assess the margins. ESD allows the lesion to be removed in one piece regardless of size, which is preferred when submucosal invasion is suspected or the lesion is bulky, but it takes longer and demands more technical skill.¹⁵ In practice, EMR followed by RFA of the remaining flat Barrett’s tissue is the most common combination.

Cryotherapy is a newer ablation option that destroys tissue by freezing it with compressed liquid nitrogen or nitrous oxide. It can serve as either a first-line treatment or a salvage option for patients whose dysplasia recurs after RFA.¹⁶

When Surgery Becomes the Better Option

Esophagectomy, the surgical removal of part or all of the esophagus, was once the default treatment for high-grade dysplasia. It is a major operation with significant morbidity, and for most patients, endoscopic therapy now offers equivalent long-term survival at lower cost and with fewer complications. Cost-effectiveness modeling found that endoscopic mucosal resection combined with RFA produced quality-adjusted survival equivalent to esophagectomy while costing significantly less over twenty years, and this advantage held across all age groups studied.¹⁷

That said, esophagectomy still has a role. Patients with diffuse or ulcerated HGD, or those whose endoscopic biopsies suggest deeper invasion, may be better served by surgery. Endoscopic therapy also typically requires multiple sessions over months, and some patients prefer a single definitive procedure. Preserving the esophagus does carry an advantage beyond survival numbers: patients who keep their esophagus can later undergo an anti-reflux procedure (fundoplication) to control the underlying GERD, which may improve long-term quality of life.¹⁸

The Role of Acid-Suppressing Medication

Proton pump inhibitors (PPIs) are a cornerstone of medical management for anyone with Barrett’s esophagus, and they appear to do more than just relieve reflux symptoms. Two separate meta-analyses found that PPI use cut the risk of Barrett’s progressing to HGD or cancer by roughly half.^{19 20} The protective effect appears to grow with longer duration of use. Antireflux surgery (fundoplication) may also reduce dysplasia development compared to medical therapy alone.¹¹

PPIs alone do not eliminate dysplasia that’s already established. Their value is in slowing or preventing progression, making them a background treatment that runs alongside whatever endoscopic or surgical intervention is chosen. Virtually all patients with Barrett’s-related dysplasia will be placed on long-term PPI therapy.

What Happens After Successful Treatment

Even after endoscopic therapy successfully clears all visible Barrett’s tissue and dysplasia, the story isn’t over. Recurrence rates are meaningful enough that ongoing surveillance endoscopy is considered essential. In one large international study, the annual risk of recurrent dysplasia (LGD or worse) after complete eradication was about 1%, and the annual risk of recurrent HGD or cancer was about 0.7%. Recurrence typically showed up around two and a half years after the initial eradication.²¹

Surveillance schedules are being refined based on the original grade of dysplasia. For patients who had HGD or early cancer before ablation, a tighter surveillance schedule with endoscopies at six months, then annually, catches recurrences promptly while reducing the total number of procedures by about a third compared to older, more aggressive schedules. For patients who had only LGD before treatment, endoscopies at one, two, and four years appeared to balance detection with avoiding unnecessary procedures.²²

Quality of life after endoscopic therapy is a mixed picture. One long-term study found that patients scored below population averages in several quality-of-life domains even after successful treatment, though satisfaction with eating and swallowing was generally good. The oncologic outcomes supported esophageal preservation, meaning patients kept their esophagus and avoided cancer, but the ongoing surveillance burden and residual symptoms are real trade-offs that patients should know about going in.²³

Non-Endoscopic Screening Tools on the Horizon

One of the biggest challenges with esophageal dysplasia is that it can only be caught through endoscopy, a procedure that requires sedation, specialist time, and significant cost. Many people with undiagnosed Barrett’s esophagus never get screened at all. Several non-endoscopic devices are in development that could change this.

The Cytosponge is a small sponge inside a dissolvable capsule that patients swallow on a string. Once the capsule dissolves in the stomach, the sponge is pulled back up through the esophagus, collecting cells along the way. Those cells are then tested for a biomarker called trefoil factor 3 (TFF3), which flags Barrett’s tissue. Similar devices include EsophaCap and EsoCheck, a balloon-based tool that can be paired with tests for methylated DNA markers.^{24 25} These devices can be used in a regular doctor’s office without sedation, which could dramatically expand screening access. None have fully replaced endoscopy yet, but they represent one of the most promising frontiers for catching Barrett’s and dysplasia earlier, when treatment is simplest and most effective.

The Economics of Treating Dysplasia Early

For patients weighing their options, the cost-effectiveness data is reassuring about endoscopic therapy. For high-grade dysplasia, RFA is both more effective and less costly than esophagectomy, meaning it dominates the comparison in economic terms. One analysis put the probability of RFA being the better value at 83% compared to surgery.²⁶ For low-grade dysplasia, the calculation is slightly more nuanced because many LGD patients will never progress, so treating everyone with RFA means treating some people who didn’t need it. Even so, RFA remained cost-effective compared to surveillance alone, with the additional cost per quality-adjusted year of life well within standard thresholds for worthwhile medical interventions.²⁷ The trade-off for LGD ultimately comes down to individual risk tolerance: some patients prefer to treat and eliminate the worry, while others prefer close surveillance to avoid procedures they may never need.